SEC Form 4 · accession 0001615774-17-000860
Tonix Pharmaceuticals Holding Corp. · TNXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seth Lederman
Officer — Chief Executive Officer · Director
Period of report
Mar 1, 2017
Accepted (ET)
Mar 1, 2017 · 9:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001430306
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $0.55 | Mar 1, 2017 | A | 160,000 | A | — | Mar 1, 2027 | Common Stock | 160,000 | 160,000 | D |
| Stock OptionF2,F3 | $0.55 | Mar 1, 2017 | A | 160,000 | A | — | Mar 1, 2027 | Common Stock | 160,000 | 160,000 | D |
Explanation of responses
- F1The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F2The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan.
- F3The option vests 50% if the Issuer achieves enrollment of 250 patients in its HONOR study by December 31, 2017, with the remaining 50% vesting 1% for each patient that is enrolled in the HONOR study by December 31, 2017 in excess of 250, subject to a one year minimum service period prior to vesting.